ACADIA Pharmaceuticals Inc. vs Newmont Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.52 (market cap $5.07B), while Newmont Corporation trades at $119.19 (market cap $123.50B). The key difference: Newmont Corporation is far larger — about 24.4× ACADIA Pharmaceuticals Inc.'s market cap, and Newmont Corporation pays a 0.89% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | NEM | |
|---|---|---|
Market Cap | $5.07B | $123.50B |
Sector | Health | Basic Materials |
52-Week High | $29.41 | $131.95 |
52-Week Low | $20.06 | $67.38 |
Enterprise Value | $4.19B | $120.09B |
Dividend Yield | — | 0.89% |
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →